← Leaderboards
Carolyn Y Ho
Brigham And Women'S Hospital
$13,169,103
Attributed
$19,536,050
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$19,536,050 · 5
By mechanism
P50$11,233,072 · 1
R01$5,898,403 · 1
P20$1,500,823 · 1
K23$795,360 · 1
F32$108,392 · 1
Top collaborators
- Christine E. Seidman7 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Ravi Thadhani$43,973,148
- Daniel Aeschbach$2,974,713
- Gregory L Stahl$14,189,628
- Steven C. Hunt$31,842,089
- Jan Lammerding$11,049,730
Others in their field
Top investigators on “Genotype”
- David R. Weir · University Of Michigan At Ann Arbor$303,033,420
- Richard A Gibbs · Baylor College Of Medicine$211,329,145
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Stacey Gabriel · Massachusetts Institute Of Technology$153,486,482
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$141,132,078
Research focus
GenotypeGeneticCardiovascular DiseasesPhenotypeCardiacFibrosisSarcomeresHypertrophic CardiomyopathyMutationGenetic Predisposition To DiseaseInsightLeft Ventricular HypertrophyStructureImageMolecularDiagnosisHeart FailureHeart DiseasesArrhythmiaCalciumFunctional DisorderMuscle CellsDiltiazemBase
Grant awards (18)
Hypertrophic Cardiomyopathy: Understanding the Heterogeneity of Disease Expression and Outcomes$1,272,161
R01 · FY2024 · HL · contact PI
Hypertrophic Cardiomyopathy: Understanding the Heterogeneity of Disease Expression and Outcomes$1,437,743
R01 · FY2023 · HL · contact PI
Hypertrophic Cardiomyopathy: Understanding the Heterogeneity of Disease Expression and Outcomes$1,590,760
R01 · FY2022 · HL · contact PI
Hypertrophic Cardiomyopathy: Understanding the Heterogeneity of Disease Expression and Outcomes$1,597,739
R01 · FY2021 · HL · contact PI
Using Genetics For Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$2,146,465
P50 · FY2017 · HL · contact PI
Using Genetics For Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$2,198,323
P50 · FY2016 · HL · contact PI
Using Genetics For Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$2,237,613
P50 · FY2015 · HL · contact PI
Using Genetics For Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$2,255,474
P50 · FY2013 · HL · contact PI
Using Genetics For Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$2,395,197
P50 · FY2012 · HL · contact PI
Using Genetics for Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$733,396
P20 · FY2011 · HL · contact PI
Using Genetics for Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy$767,427
P20 · FY2010 · HL · contact PI
Diagnostic and Treatment Strategies for Preclinical HCM$157,200
K23 · FY2009 · HL · contact PI
Diagnostic and Treatment Strategies for Preclinical HCM$158,520
K23 · FY2008 · HL · contact PI
Diagnostic and Treatment Strategies for Preclinical HCM$157,800
K23 · FY2007 · HL · contact PI
Diagnostic and Treatment Strategies for Preclinical HCM$160,920
K23 · FY2006 · HL · contact PI
Diagnostic and Treatment Strategies for Preclinical HCM$160,920
K23 · FY2005 · HL
Diastolic Function in Hypertrophic Cardiomyopathy$56,308
F32 · FY2003 · HL
Diastolic Function in Hypertrophic Cardiomyopathy$52,084
F32 · FY2002 · HL